tirzepatide vs semaglutide cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice Tirzepatide Versus Semaglutide and Cardiovascular

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence

In its purest form, semaglutidea GLP-1 (glucagon-like peptide-1) receptor agonistis dissolved in a sterile base, usually consisting of water and specific preservatives or buffers to maintain stability

1 Other sleep outcomes did not move significantly

For secondary prevention (people with established cardiovascular disease), targets are often 70 mg/dL or even lower depending on individual risk

10.1126/science.1166323 [DOI] [PubMed] [Google Scholar] 15.Curry S, Brick P, Franks NP

Will I need to re-titrate